Secondly, given the marked effect of HER2 expression on PTK activity observed in patients of both breast cancer types compared to HV, we tested if HER-2 status could be predicted in cancer patients from the kinome perturbation in their circulating neutrophils. The gene discussed is ERBB2; the disease is breast carcinoma.